William Blair analyst Matt Phipps has maintained their bullish stance on AUTL stock, giving a Buy rating on April 10.
Matt Phipps has given his Buy rating due to a combination of factors surrounding Autolus Therapeutics’ promising developments in treating lupus nephritis. The company has presented encouraging initial results from a Phase I trial using its CD19 CAR-T therapy, obe-cel, which demonstrated a 50% complete renal response rate. This positive outcome suggests potential efficacy and safety, as no severe adverse effects were reported.
Furthermore, Autolus has outlined a clear and feasible path for accelerated approval, which includes a single-arm trial aimed at supporting this process. The FDA’s support for this development path, along with a well-defined regulatory framework, adds confidence to the company’s prospects in the autoimmune disease space. These strategic advancements and regulatory endorsements underpin the Buy rating, as they position Autolus favorably for future growth and success.
In another report released on April 10, Needham also maintained a Buy rating on the stock with a $10.00 price target.